Blog

Careers

Advertise

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2022
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2022
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News

HSCA Urges DEA to Take Steps to Mitigate Shortages of Injectable Opioids

March 9, 2018 by admin 2018 Press Releases 0 comments
Healthcare Supply Chain Association (HSCA) President and CEO Todd Ebert, R.Ph., today released the following statement encouraging the Drug Enforcement Administration (DEA) to take critical steps to ease current shortages of injectable opioids:
“Hospitals and other healthcare providers are currently experiencing critical shortages of a number of injectable opioid medications – including morphine, hydromorphone, and fentanyl – that are an essential element of treatment for post – surgical and medical pain management. Without the necessary opioids available, many medical procedures would have to be postponed or cancelled, jeopardizing the wellbeing of patients across the country. Controlling narcotics use – particularly outpatient prescription opioid abuse – remains a public health priority that HSCA supports.”
Read the full press release…
Next

Related Posts

HSCA Joins Leading Healthcare Organizations in Supporting the CREATES Act (S.974)
June 7, 2018

We, the undersigned, commend you for your leadership and commitment to reducing...

Learn more
Comments of the Healthcare Supply Chain Association on the Department of Health and Human Services Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
July 16, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Releases Second Annual Report on Value GPOs Deliver to the Healthcare Supply Chain
August 21, 2018

Washington, DC (August 21, 2018) – The Healthcare Supply Chain Association...

Learn more
HSCA Comments on DEA Proposed Rule on Opioid Production Limits
May 4, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more

Our Office

Healthcare Supply Chain Association
1341 G Street NW Suite 600
Washington, DC 20005

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Support Letter to the House Committee on Energy & Commerce on House Passage of FDA User Fee Reauthorizations
    June 30, 2022
  • ANALYSIS: GPOs Helped Increase Domestic Manufacturing Capacity, Protected Hospitals and Patients from Thousands of Fraudulent Sellers, and Helped Identify and Bring New Suppliers to Market to Avert Supply and Drug Shortages During COVID-19
    April 20, 2022